LncRNA TINCR is associated with clinical progression and serves as tumor suppressive role in prostate cancer
10.2147/cmar.s170526 · doi-reference
10.1016/j.cancergencyto.2007.12.004
10.1016/j.cancergencyto.2007.12.004 · doi-reference
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
10.1038/leu.2014.232 · doi-reference
A 19-gene expression signature as a predictor of survival in colorectal cancer
10.1186/s12920-016-0218-1 · doi-reference
Identification of markers of prostate cancer progression using candidate gene expression
10.1038/bjc.2011.490 · doi-reference
A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides
10.1038/jid.2012.117 · doi-reference
DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer
10.18632/oncotarget.10886 · doi-reference
10.1371/journal.pone.0002994
10.1371/journal.pone.0002994 · doi-reference
10.1073/pnas.0401994101
10.1073/pnas.0401994101 · doi-reference
10.1038/onc.2009.300
10.1038/onc.2009.300 · doi-reference
10.1038/ncomms8769
10.1038/ncomms8769 · doi-reference
Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma
10.2174/0929867321666140601204513 · doi-reference
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer
10.1002/path.3035 · doi-reference
10.1038/nrc2781
10.1038/nrc2781 · doi-reference
10.4161/23723548.2014.970484
10.4161/23723548.2014.970484 · doi-reference
10.1038/embor.2012.61
10.1038/embor.2012.61 · doi-reference
TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer
10.1038/s41419-018-0434-z · doi-reference
TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer
10.1016/j.ijbiomac.2018.09.168 · doi-reference
Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma
10.1016/j.bbrc.2018.03.129 · doi-reference
10.18632/oncotarget.16038
10.18632/oncotarget.16038 · doi-reference
TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion
10.3892/ol.2016.5332 · doi-reference
Role of CCT chaperonin in the disassembly of mitotic checkpoint complexes
10.1073/pnas.1620451114 · doi-reference
The spindle-assembly checkpoint, aneuploidy, and gastrointestinal cancer
10.1056/nejme1008017 · doi-reference
Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer
10.1016/j.cancergencyto.2006.11.012 · doi-reference
10.1158/0008-5472.can-12-1991
10.1158/0008-5472.can-12-1991 · doi-reference
10.1038/ng1449
10.1038/ng1449 · doi-reference
10.1016/j.semcdb.2011.03.002
10.1016/j.semcdb.2011.03.002 · doi-reference
10.1038/nrc1714
10.1038/nrc1714 · doi-reference
p53 haploinsufficiency and functional abnormalities in multiple myeloma
10.1038/leu.2014.102 · doi-reference
TRIP13-deficient tubular epithelial cells are susceptible to apoptosis following acute kidney injury
10.1038/srep43196 · doi-reference
10.1016/j.toxlet.2015.12.004
10.1016/j.toxlet.2015.12.004 · doi-reference
10.1016/j.tibs.2010.09.005
10.1016/j.tibs.2010.09.005 · doi-reference
10.1093/carcin/bgq133
10.1093/carcin/bgq133 · doi-reference
10.1101/gad.314351.118
10.1101/gad.314351.118 · doi-reference
10.1093/nar/gkx247
10.1093/nar/gkx247 · doi-reference
10.1172/jci59954
10.1172/jci59954 · doi-reference
10.1158/0008-5472.can-08-4833
10.1158/0008-5472.can-08-4833 · doi-reference
10.1146/annurev-genet-110711-155540
10.1146/annurev-genet-110711-155540 · doi-reference
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer
10.1038/ncomms5527 · doi-reference
10.1371/journal.pgen.1006845
10.1371/journal.pgen.1006845 · doi-reference
